Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41586-021-03653-6 http://scihub22266oqcxt.onion/10.1038/s41586-021-03653-6 34044428!ä!34044428 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nature 2021 ; 595 (7868): 572-577 Nephropedia Template TP {{tp|p=34044428|t=2021. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans |pdf=|usr=}}{{34044428}} gab.com Text BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=34044428 #FOAvip BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has demonstrated 95% efficacy in preventing COVID-19(1). Here we extend a previous phase-I/II trial report(2) by presenting data on the immune response induced by BNT162b2 prime-boost vaccination from an additional phase-I/II trial in healthy adults (18-55 years old). BNT162b2 elicited strong antibody responses: at one week after the boost, SARS-CoV-2 serum geometric mean 50% neutralizing titres were up to 3.3-fold above those observed in samples from individuals who had recovered from COVID-19. Sera elicited by BNT162b2 neutralized 22 pseudoviruses bearing the S of different SARS-CoV-2 variants. Most participants had a strong response of IFNgamma(+) or IL-2(+) CD8(+) and CD4(+) T helper type 1 cells, which was detectable throughout the full observation period of nine weeks following the boost. Using peptide-MHC multimer technology, we identified several BNT162b2-induced epitopes that were presented by frequent MHC alleles and conserved in mutant strains. One week after the boost, epitope-specific CD8(+) T cells of the early-differentiated effector-memory phenotype comprised 0.02-2.92% of total circulating CD8(+) T cells and were detectable (0.01-0.28%) eight weeks later. In summary, BNT162b2 elicits an adaptive humoral and poly-specific cellular immune response against epitopes that are conserved in a broad range of variants, at well-tolerated doses. Twit Text FOAVip BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=34044428 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34044428 #FOAvip English Wikipedia <ref>{{Cite pmid|34044428}}</ref> BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans #MMPMID34044428 Sahin U; Muik A; Vogler I; Derhovanessian E; Kranz LM; Vormehr M; Quandt J; Bidmon N; Ulges A; Baum A; Pascal KE; Maurus D; Brachtendorf S; Lorks V; Sikorski J; Koch P; Hilker R; Becker D; Eller AK; Grutzner J; Tonigold M; Boesler C; Rosenbaum C; Heesen L; Kuhnle MC; Poran A; Dong JZ; Luxemburger U; Kemmer-Bruck A; Langer D; Bexon M; Bolte S; Palanche T; Schultz A; Baumann S; Mahiny AJ; Boros G; Reinholz J; Szabo GT; Kariko K; Shi PY; Fontes-Garfias C; Perez JL; Cutler M; Cooper D; Kyratsous CA; Dormitzer PR; Jansen KU; Tureci O Nature 2021[Jul]; 595 (7868): 572-577 PMID34044428show ga BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has demonstrated 95% efficacy in preventing COVID-19(1). Here we extend a previous phase-I/II trial report(2) by presenting data on the immune response induced by BNT162b2 prime-boost vaccination from an additional phase-I/II trial in healthy adults (18-55 years old). BNT162b2 elicited strong antibody responses: at one week after the boost, SARS-CoV-2 serum geometric mean 50% neutralizing titres were up to 3.3-fold above those observed in samples from individuals who had recovered from COVID-19. Sera elicited by BNT162b2 neutralized 22 pseudoviruses bearing the S of different SARS-CoV-2 variants. Most participants had a strong response of IFNgamma(+) or IL-2(+) CD8(+) and CD4(+) T helper type 1 cells, which was detectable throughout the full observation period of nine weeks following the boost. Using peptide-MHC multimer technology, we identified several BNT162b2-induced epitopes that were presented by frequent MHC alleles and conserved in mutant strains. One week after the boost, epitope-specific CD8(+) T cells of the early-differentiated effector-memory phenotype comprised 0.02-2.92% of total circulating CD8(+) T cells and were detectable (0.01-0.28%) eight weeks later. In summary, BNT162b2 elicits an adaptive humoral and poly-specific cellular immune response against epitopes that are conserved in a broad range of variants, at well-tolerated doses. |Adolescent[MESH] |Adult[MESH] |Antibodies, Neutralizing/*immunology[MESH] |Antibodies, Viral/*immunology[MESH] |BNT162 Vaccine[MESH] |CD8-Positive T-Lymphocytes/immunology[MESH] |COVID-19 Vaccines/administration & dosage/adverse effects/*immunology[MESH] |COVID-19/*immunology/virology[MESH] |Epitopes, T-Lymphocyte/immunology[MESH] |Female[MESH] |Humans[MESH] |Immunoglobulin G/immunology[MESH] |Immunologic Memory[MESH] |Interferon-gamma/immunology[MESH] |Interleukin-2/immunology[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2/chemistry/*immunology[MESH] |Spike Glycoprotein, Coronavirus/chemistry/immunology[MESH] |T-Lymphocytes/*immunology[MESH] |Th1 Cells/immunology[MESH]BNT162b2 vaccine induces neutralizing antibodies and poly-specific T c(epmc).pdf DeepDyve Pubget Overpricing